Recombinant Mouse Gck protein, His & T7-tagged

• Cat.No.: Gck-748M
• Product Overview: Recombinant Mouse Gck aa. (Asp3~Val226 (Accession # P52792)) fused with N-terminal His & T7 tag was produced in E. coli cells.

Specification

• Source: E. coli
• Species: Mouse
• Tag: His&T7
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 29.2kDa
• Protein length: Asp3~Val226 (Accession # P52792)
• Endotoxin: <1.0EU per 1µg (determined by the LAL method)
• Purity: >95%
• Characteristic: The isoelectric point is 5.3.
• Applications: SDS-PAGE; WB; ELISA; IP.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Storage buffer: Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.
• Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4.

Gene Information

• Gene Name: Gck glucokinase [ Mus musculus (house mouse) ]
• Official Symbol: Gck
• Synonyms: Gk; GLK; HK4; HKIV; HXKP; Hlb62; MODY2; Gls006; HK IV; hexokinase type IV; hexokinase-4; hexokinase-D; glucokinase
• Gene ID: 103988
• mRNA Refseq: NM_001287386.1
• Protein Refseq: NP_001274315.1
• UniProt ID: P52792

Reviews

03/22/2021

I confidently recommend the GCK protein to any researcher seeking a superior protein that not only fulfills their experimental needs but is also backed by unparalleled support from the manufacturer.

08/06/2019

This has greatly facilitated my experimental workflow, ensuring a readily available and dependable protein source whenever I need it.

09/23/2018

Its high quality, coupled with the manufacturer's exceptional technical support, make it a reliable and effective choice for addressing my scientific inquiries.

Q&As

Are there ongoing clinical trials focusing on ERBB3 inhibitors?

Clinical trials exploring ERBB3 inhibitors or drugs targeting the ERBB3 pathway are ongoing to evaluate their effectiveness and safety.

Can ERBB3 inhibitors be used in combination with other cancer therapies?

Yes, combining ERBB3 inhibitors with other targeted therapies or chemotherapy is being explored to enhance treatment efficacy.

How does ERBB3 contribute to resistance to certain cancer therapies?

ERBB3 activation has been associated with resistance to some targeted therapies, such as EGFR inhibitors, making it a challenging target in cancer treatment.

Can ERBB3 be used as a biomarker for prognosis in cancer patients?

Yes, elevated ERBB3 expression has been linked to poor prognosis in certain cancers, serving as a potential biomarker for patient outcomes.

How does ERBB3 interact with other receptors in the EGFR family?

ERBB3 can form heterodimers with other EGFR family members, such as EGFR and HER2, leading to the activation of downstream signaling pathways.